8.FDA approves tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer. News release. FDA. November 10, 2022. Accessed February 22, 2023. https://www.fda.gov
近日,durvalumab(度伐利尤单抗,Imfinzi)和tremelimumab(Imjudo)的双免疫联合疗法获欧盟批准用于晚期或不可切除肝细胞癌(HCC)肝癌的一线治疗,或者联合铂类化疗用于一线治疗转移性非小细胞肺癌(NSCLC) [1] 。 HIMALAYA试验 HIMALAYA试验为一项随机、开放标签 、多中心全球Ⅲ期试验,16个国家的181个中心参与。研究招募ECOG ...
3. Peters S, et al. Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC. Presented at IASLC 2022 World Conference on Lung Cancer, 9-13 Septemb...
EGFR/ALK野生型mNSCLC患者(n=1,013)被随机分组(1∶1∶1),接受tremelimumab 75 mg + durvalumab 1,500 mg和铂类化疗,最长4个周期,21日为1个周期,之后每4周1次durvalumab治疗,直至疾病进展,并接受1次额外tremelimumab剂量。Durvalumab +化疗最多4个周期,每个周期21日,之后每4周1次Durvalumab,直至疾病进展;或长...
所有56例接受durvalumab 10-20毫克/千克q2w 或 q4w与tremelimumab 1毫克/千克联合治疗的患者数据显示,进展期NSCLC群体中的安全性属可处治。30%的患者发生 ≥1次相关3/4级不良事件(AE),16%的中断治疗可归咎于某一相关不良事件。 美国佛罗里达州坦帕市Moffitt癌症中心胸腔肿瘤科主任Scott J. Antonia博士说:“durvalu...
3. Peters S, et al. Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC. Presented at IASLC 2022 World Conference on Lung Cancer, 9-13 September 2022. 4. Frank R, et al. Clinical and Pathological Characteristics...
The combination of durvalumab and tremelimumab is being tested in lung cancer, bladder cancer, and liver cancer settings, according to the press release. REFERENCE Imfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line Stage I...
2022年11月10日,美国FDA宣布已批准阿斯利康(AstraZeneca)抗CTLA-4抗体tremelimumab(Imjudo)与抗PD-L1单克隆抗体durvalumab(Imfinzi,度伐利尤单抗)联合化疗构成的三重组合疗法,用于不携带表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)融合的转移性非小细胞肺癌(NSCLC)成年患者。
durvalumabetoposideextensive-stage small-cell lung cancerplatinumtremelimumabDurvalumab plus etoposide-platinum (DEP) showed sustained overall survival improvements in patients with extensive-stage small-cell lung cancer (ES-SCLC) compared to etoposide-platinum (EP), but adding tremelimumab to DEP (DTEP) ...
Phase II Single Arm Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis (STRIDE in CP-B) This is a single-arm, phase II study of patients with advanced liver cancer or hepatocellular carcinoma (HCC) who are eligible for...